Join
Live feed
·
PRReleasevia Quantisnow
Ligand Pharmaceuticals Incorporated logo
Travere Therapeutics Inc. logo

Ligand's Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

ByQuantisnow·Wall Street's wire, on your screen.
LGND· Ligand Pharmaceuticals IncorporatedTVTX· Travere Therapeutics Inc.
Health Care
Ligand's Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy | Quantisnow